Try our Investor Tool
Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Try our Investor Tool
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Destiny Pharma Plc
Clear Filter
Search
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
»
Date / Time
Source
Company
Sector
Market Cap
Announcement
28Jul22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Chair’s Investor Update
26Jul22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Publication of new data on NTCD-M3
19Jul22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Positive update from US FDA on XF-73 Phase 3
12Jul22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Grant from the Cystic Fibrosis Foundation
07Jul22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Publication of XF-73 drug synergy data
05Jul22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - New XF-73 research programme
08Jun22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Grant of share options
27May22 11:56
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Result of Annual General Meeting & Strategy Update
26May22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Board Changes
12May22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Landmark NTCD-M3 data to be presented at Anaerobe
03May22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Destiny Pharma appoints Dr Yuri Martina as CMO
27Apr22 15:34
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Posting of Annual Report and Notice of AGM
26Apr22 15:30
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Director/PDMR Shareholding
12Apr22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Audited results for year ended 31 December 2021
04Apr22 14:45
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Notice of Results
04Apr22 14:37
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Notification of Major Holdings
31Mar22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - To present data at ECCMID Congress
28Mar22 11:30
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Result of General Meeting and Total Voting Rights
25Mar22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Result of Open Offer
22Mar22 10:30
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
08Mar22 12:30
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Fundraising
08Feb22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Positive feedback from EMA on XF-73 Nasal gel Ph 3
01Feb22 16:11
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
01Feb22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Positive data in XF-73 Dermal study with NIAID
31Jan22 14:30
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
25Jan22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Grant of share options
24Jan22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Clinical and commercial opportunity of NTCD-M3
21Jan22 07:15
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Destiny Pharma Lancet Report
17Jan22 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Strategy/Company/Ops Update
21Dec21 16:35
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
17Dec21 09:46
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Grant of share options
15Nov21 14:26
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Directorate Change
04Nov21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - SAB Member Prof. Gerding is Keynote at C.diff Conf
18Oct21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Study gives strong support for potential of XF-73
27Sep21 15:18
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Director/PDMR Shareholding
27Sep21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Expansion of clinical pipeline
09Sep21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Interim results for six months ended 30 June 2021
23Aug21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Notice of Interim Results
02Aug21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Secondary endpoint analysis from Phase 2b trial
09Jul21 08:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - XF-73 Phase 2b data to be presented at ECCMID
06Jul21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - NTCD-M3 RD Agreement with US Dept Veterans Affairs
02Jul21 08:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Scientific Advisor Gerding chairs C Diff symposium
29Jun21 08:24
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - DEST to present at Shares & AJ Bell Webinar 6/7/21
10Jun21 17:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Director Dealing
10Jun21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Result of AGM
02Jun21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Further information re AGM
19May21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00
RNS-R
Destiny Pharma Plc
Health
£29.3m
Conference Attendance for May 2021
04May21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Posting of Annual Report and Notice of AGM
30Apr21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Director Dealing
23Apr21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Director Dealing
15Apr21 08:00
RNS-R
Destiny Pharma Plc
Health
£29.3m
FY 2020 Investor Presentation
14Apr21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Final Results
29Mar21 12:45
RNS
Destiny Pharma Plc
Health
£29.3m
Exercise of Options and Total Voting Rights
29Mar21 12:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15
RNS
Destiny Pharma Plc
Health
£29.3m
Exercise of Options and Total Voting Rights
29Mar21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Notice of Results
15Mar21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15
RNS
Destiny Pharma Plc
Health
£29.3m
Exercise of Options and Total Voting Rights
10Mar21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31
RNS
Destiny Pharma Plc
Health
£29.3m
Grant of Share Options
21Jan21 08:28
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma Investor Presentation
07Jan21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma: Directors Dealings
06Jan21 08:00
RNS-R
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09
RNS
Destiny Pharma Plc
Health
£29.3m
Grant of share options
22Dec20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Update on the recently acquired NTCD-M3 programme
01Dec20 17:23
RNS
Destiny Pharma Plc
Health
£29.3m
Holding(s) in Company
30Nov20 14:00
RNS
Destiny Pharma Plc
Health
£29.3m
Holding(s) in Company
26Nov20 10:50
RNS
Destiny Pharma Plc
Health
£29.3m
Result of General Meeting and Total Voting Rights
25Nov20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Result of Open Offer
09Nov20 16:25
RNS
Destiny Pharma Plc
Health
£29.3m
Fundraising and Acquisition
12Oct20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Clinical Study Patient Recruitment Update
17Sep20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Update on Phase 2b clinical study of XF-73
17Sep20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Notice of Results
07Sep20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Collaboration to co-develop treatment for COVID-19
11Aug20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Positive interim safety review of XF-73 phase 2b
27Jul20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Update on Phase 2b clinical study of XF-73
15Jul20 07:00
RNS-R
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00
RNS
Destiny Pharma Plc
Health
£29.3m
Cancellation and Grant of Options
10Jun20 12:30
RNS
Destiny Pharma Plc
Health
£29.3m
Result of AGM
09Jun20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Grant awarded for Cardiff University collaboration
12May20 15:15
RNS
Destiny Pharma Plc
Health
£29.3m
Posting of Annual Report and Notice of AGM
04May20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Independent review supports the potential of XF-73
29Apr20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Final Results
24Apr20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Notice of Results
03Mar20 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Clinical and Business Update
20Jan20 07:00
RNS-R
Destiny Pharma Plc
Health
£29.3m
Update on the development of XF drug formulations
17Dec19 07:00
RNS-R
Destiny Pharma Plc
Health
£29.3m
APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Directorate Change
02Dec19 07:00
RNS
Destiny Pharma Plc
Health
£29.3m
Destiny to present at UK-China AMR Workshop
15Nov19 07:30
RNS-R
Destiny Pharma Plc
Health
£29.3m
Presentation at the Investival Showcase
06Nov19 07:00
RNS-R
Destiny Pharma Plc
Health
£29.3m
Destiny Pharma to present at World AMR Congress
«
1
2
»
Date / Time
Source
Company
% Chg
28Jul22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Chair’s Investor Update
26Jul22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Publication of new data on NTCD-M3
19Jul22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Positive update from US FDA on XF-73 Phase 3
12Jul22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Grant from the Cystic Fibrosis Foundation
07Jul22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Publication of XF-73 drug synergy data
05Jul22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - New XF-73 research programme
08Jun22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Grant of share options
27May22 11:56
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Result of Annual General Meeting & Strategy Update
26May22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Board Changes
12May22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Landmark NTCD-M3 data to be presented at Anaerobe
03May22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Destiny Pharma appoints Dr Yuri Martina as CMO
27Apr22 15:34
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Posting of Annual Report and Notice of AGM
26Apr22 15:30
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Director/PDMR Shareholding
12Apr22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Audited results for year ended 31 December 2021
04Apr22 14:45
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Notice of Results
04Apr22 14:37
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Notification of Major Holdings
31Mar22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - To present data at ECCMID Congress
28Mar22 11:30
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Result of General Meeting and Total Voting Rights
25Mar22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Result of Open Offer
22Mar22 10:30
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
08Mar22 12:30
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Fundraising
08Feb22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Positive feedback from EMA on XF-73 Nasal gel Ph 3
01Feb22 16:11
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
01Feb22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Positive data in XF-73 Dermal study with NIAID
31Jan22 14:30
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
25Jan22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Grant of share options
24Jan22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Clinical and commercial opportunity of NTCD-M3
21Jan22 07:15
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Destiny Pharma Lancet Report
17Jan22 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Strategy/Company/Ops Update
21Dec21 16:35
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
17Dec21 09:46
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Grant of share options
15Nov21 14:26
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Directorate Change
04Nov21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - SAB Member Prof. Gerding is Keynote at C.diff Conf
18Oct21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Study gives strong support for potential of XF-73
27Sep21 15:18
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Director/PDMR Shareholding
27Sep21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Expansion of clinical pipeline
09Sep21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Interim results for six months ended 30 June 2021
23Aug21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Notice of Interim Results
02Aug21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Secondary endpoint analysis from Phase 2b trial
09Jul21 08:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - XF-73 Phase 2b data to be presented at ECCMID
06Jul21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - NTCD-M3 RD Agreement with US Dept Veterans Affairs
02Jul21 08:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Scientific Advisor Gerding chairs C Diff symposium
29Jun21 08:24
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - DEST to present at Shares & AJ Bell Webinar 6/7/21
10Jun21 17:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Director Dealing
10Jun21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Result of AGM
02Jun21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Further information re AGM
19May21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00
RNS-R
Destiny Pharma Plc
0.00%
Conference Attendance for May 2021
04May21 07:00
RNS
Destiny Pharma Plc
0.00%
Posting of Annual Report and Notice of AGM
30Apr21 07:00
RNS
Destiny Pharma Plc
0.00%
Director Dealing
23Apr21 07:00
RNS
Destiny Pharma Plc
0.00%
Director Dealing
15Apr21 08:00
RNS-R
Destiny Pharma Plc
0.00%
FY 2020 Investor Presentation
14Apr21 07:00
RNS
Destiny Pharma Plc
0.00%
Final Results
29Mar21 12:45
RNS
Destiny Pharma Plc
0.00%
Exercise of Options and Total Voting Rights
29Mar21 12:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15
RNS
Destiny Pharma Plc
0.00%
Exercise of Options and Total Voting Rights
29Mar21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00
RNS
Destiny Pharma Plc
0.00%
Notice of Results
15Mar21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15
RNS
Destiny Pharma Plc
0.00%
Exercise of Options and Total Voting Rights
10Mar21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00
RNS
Destiny Pharma Plc
0.00%
Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31
RNS
Destiny Pharma Plc
0.00%
Grant of Share Options
21Jan21 08:28
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma Investor Presentation
07Jan21 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny Pharma: Directors Dealings
06Jan21 08:00
RNS-R
Destiny Pharma Plc
0.00%
Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00
RNS
Destiny Pharma Plc
0.00%
Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09
RNS
Destiny Pharma Plc
0.00%
Grant of share options
22Dec20 07:00
RNS
Destiny Pharma Plc
0.00%
Update on the recently acquired NTCD-M3 programme
01Dec20 17:23
RNS
Destiny Pharma Plc
0.00%
Holding(s) in Company
30Nov20 14:00
RNS
Destiny Pharma Plc
0.00%
Holding(s) in Company
26Nov20 10:50
RNS
Destiny Pharma Plc
0.00%
Result of General Meeting and Total Voting Rights
25Nov20 07:00
RNS
Destiny Pharma Plc
0.00%
Result of Open Offer
09Nov20 16:25
RNS
Destiny Pharma Plc
0.00%
Fundraising and Acquisition
12Oct20 07:00
RNS
Destiny Pharma Plc
0.00%
Clinical Study Patient Recruitment Update
17Sep20 07:00
RNS
Destiny Pharma Plc
0.00%
Update on Phase 2b clinical study of XF-73
17Sep20 07:00
RNS
Destiny Pharma Plc
0.00%
Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00
RNS
Destiny Pharma Plc
0.00%
Notice of Results
07Sep20 07:00
RNS
Destiny Pharma Plc
0.00%
Collaboration to co-develop treatment for COVID-19
11Aug20 07:00
RNS
Destiny Pharma Plc
0.00%
Positive interim safety review of XF-73 phase 2b
27Jul20 07:00
RNS
Destiny Pharma Plc
0.00%
Update on Phase 2b clinical study of XF-73
15Jul20 07:00
RNS-R
Destiny Pharma Plc
0.00%
Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00
RNS
Destiny Pharma Plc
0.00%
Cancellation and Grant of Options
10Jun20 12:30
RNS
Destiny Pharma Plc
0.00%
Result of AGM
09Jun20 07:00
RNS
Destiny Pharma Plc
0.00%
Grant awarded for Cardiff University collaboration
12May20 15:15
RNS
Destiny Pharma Plc
0.00%
Posting of Annual Report and Notice of AGM
04May20 07:00
RNS
Destiny Pharma Plc
0.00%
Independent review supports the potential of XF-73
29Apr20 07:00
RNS
Destiny Pharma Plc
0.00%
Final Results
24Apr20 07:00
RNS
Destiny Pharma Plc
0.00%
Notice of Results
03Mar20 07:00
RNS
Destiny Pharma Plc
0.00%
Clinical and Business Update
20Jan20 07:00
RNS-R
Destiny Pharma Plc
0.00%
Update on the development of XF drug formulations
17Dec19 07:00
RNS-R
Destiny Pharma Plc
0.00%
APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00
RNS
Destiny Pharma Plc
0.00%
Directorate Change
02Dec19 07:00
RNS
Destiny Pharma Plc
0.00%
Destiny to present at UK-China AMR Workshop
15Nov19 07:30
RNS-R
Destiny Pharma Plc
0.00%
Presentation at the Investival Showcase
06Nov19 07:00
RNS-R
Destiny Pharma Plc
0.00%
Destiny Pharma to present at World AMR Congress
«
1
2
»
Date / Time
Company
% Chg
28Jul22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Chair’s Investor Update
26Jul22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Publication of new data on NTCD-M3
19Jul22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Positive update from US FDA on XF-73 Phase 3
12Jul22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Grant from the Cystic Fibrosis Foundation
07Jul22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Publication of XF-73 drug synergy data
05Jul22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - New XF-73 research programme
08Jun22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Grant of share options
27May22 11:56
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Result of Annual General Meeting & Strategy Update
26May22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Board Changes
12May22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Landmark NTCD-M3 data to be presented at Anaerobe
03May22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Destiny Pharma appoints Dr Yuri Martina as CMO
27Apr22 15:34
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Posting of Annual Report and Notice of AGM
26Apr22 15:30
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Director/PDMR Shareholding
12Apr22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Audited results for year ended 31 December 2021
04Apr22 14:45
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Notice of Results
04Apr22 14:37
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Notification of Major Holdings
31Mar22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - To present data at ECCMID Congress
28Mar22 11:30
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Result of General Meeting and Total Voting Rights
25Mar22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Result of Open Offer
22Mar22 10:30
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
08Mar22 12:30
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Fundraising
08Feb22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Positive feedback from EMA on XF-73 Nasal gel Ph 3
01Feb22 16:11
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
01Feb22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Positive data in XF-73 Dermal study with NIAID
31Jan22 14:30
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
25Jan22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Grant of share options
24Jan22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Clinical and commercial opportunity of NTCD-M3
21Jan22 07:15
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Destiny Pharma Lancet Report
17Jan22 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Strategy/Company/Ops Update
21Dec21 16:35
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
17Dec21 09:46
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Grant of share options
15Nov21 14:26
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Directorate Change
04Nov21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - SAB Member Prof. Gerding is Keynote at C.diff Conf
18Oct21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Study gives strong support for potential of XF-73
27Sep21 15:18
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Director/PDMR Shareholding
27Sep21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Expansion of clinical pipeline
09Sep21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Interim results for six months ended 30 June 2021
23Aug21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Notice of Interim Results
02Aug21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Secondary endpoint analysis from Phase 2b trial
09Jul21 08:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - XF-73 Phase 2b data to be presented at ECCMID
06Jul21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - NTCD-M3 RD Agreement with US Dept Veterans Affairs
02Jul21 08:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Scientific Advisor Gerding chairs C Diff symposium
29Jun21 08:24
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - DEST to present at Shares & AJ Bell Webinar 6/7/21
10Jun21 17:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Director Dealing
10Jun21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Result of AGM
02Jun21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Further information re AGM
19May21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00
Destiny Pharma Plc
0.00%
Conference Attendance for May 2021
04May21 07:00
Destiny Pharma Plc
0.00%
Posting of Annual Report and Notice of AGM
30Apr21 07:00
Destiny Pharma Plc
0.00%
Director Dealing
23Apr21 07:00
Destiny Pharma Plc
0.00%
Director Dealing
15Apr21 08:00
Destiny Pharma Plc
0.00%
FY 2020 Investor Presentation
14Apr21 07:00
Destiny Pharma Plc
0.00%
Final Results
29Mar21 12:45
Destiny Pharma Plc
0.00%
Exercise of Options and Total Voting Rights
29Mar21 12:00
Destiny Pharma Plc
0.00%
Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15
Destiny Pharma Plc
0.00%
Exercise of Options and Total Voting Rights
29Mar21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00
Destiny Pharma Plc
0.00%
Notice of Results
15Mar21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15
Destiny Pharma Plc
0.00%
Exercise of Options and Total Voting Rights
10Mar21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00
Destiny Pharma Plc
0.00%
Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31
Destiny Pharma Plc
0.00%
Grant of Share Options
21Jan21 08:28
Destiny Pharma Plc
0.00%
Destiny Pharma Investor Presentation
07Jan21 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma: Directors Dealings
06Jan21 08:00
Destiny Pharma Plc
0.00%
Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00
Destiny Pharma Plc
0.00%
Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09
Destiny Pharma Plc
0.00%
Grant of share options
22Dec20 07:00
Destiny Pharma Plc
0.00%
Update on the recently acquired NTCD-M3 programme
01Dec20 17:23
Destiny Pharma Plc
0.00%
Holding(s) in Company
30Nov20 14:00
Destiny Pharma Plc
0.00%
Holding(s) in Company
26Nov20 10:50
Destiny Pharma Plc
0.00%
Result of General Meeting and Total Voting Rights
25Nov20 07:00
Destiny Pharma Plc
0.00%
Result of Open Offer
09Nov20 16:25
Destiny Pharma Plc
0.00%
Fundraising and Acquisition
12Oct20 07:00
Destiny Pharma Plc
0.00%
Clinical Study Patient Recruitment Update
17Sep20 07:00
Destiny Pharma Plc
0.00%
Update on Phase 2b clinical study of XF-73
17Sep20 07:00
Destiny Pharma Plc
0.00%
Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00
Destiny Pharma Plc
0.00%
Notice of Results
07Sep20 07:00
Destiny Pharma Plc
0.00%
Collaboration to co-develop treatment for COVID-19
11Aug20 07:00
Destiny Pharma Plc
0.00%
Positive interim safety review of XF-73 phase 2b
27Jul20 07:00
Destiny Pharma Plc
0.00%
Update on Phase 2b clinical study of XF-73
15Jul20 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00
Destiny Pharma Plc
0.00%
Cancellation and Grant of Options
10Jun20 12:30
Destiny Pharma Plc
0.00%
Result of AGM
09Jun20 07:00
Destiny Pharma Plc
0.00%
Grant awarded for Cardiff University collaboration
12May20 15:15
Destiny Pharma Plc
0.00%
Posting of Annual Report and Notice of AGM
04May20 07:00
Destiny Pharma Plc
0.00%
Independent review supports the potential of XF-73
29Apr20 07:00
Destiny Pharma Plc
0.00%
Final Results
24Apr20 07:00
Destiny Pharma Plc
0.00%
Notice of Results
03Mar20 07:00
Destiny Pharma Plc
0.00%
Clinical and Business Update
20Jan20 07:00
Destiny Pharma Plc
0.00%
Update on the development of XF drug formulations
17Dec19 07:00
Destiny Pharma Plc
0.00%
APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00
Destiny Pharma Plc
0.00%
Directorate Change
02Dec19 07:00
Destiny Pharma Plc
0.00%
Destiny to present at UK-China AMR Workshop
15Nov19 07:30
Destiny Pharma Plc
0.00%
Presentation at the Investival Showcase
06Nov19 07:00
Destiny Pharma Plc
0.00%
Destiny Pharma to present at World AMR Congress
«
1
2
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Blogs
Academy
Insights
News
Research Tree
The Naked Fund Manager
Ideas & Picks
Ideas Hub
Stock Pick League
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Aic Sectors
Asia Pacific
Asia Pacific Equity Income
Asia Pacific Smaller Companies
China / Greater China
Commodities & Natural Resources
Country Specialist
Europe
European Smaller Companies
Flexible Investment
Global
Global Emerging Markets
Global Equity Income
Global Smaller Companies
Growth Capital
India
Infrastructure
Japan
Japanese Smaller Companies
Latin America
Liquidity Funds
North America
North American Smaller Companies
Private Equity
Property - Europe
Property - Rest of World
Property - UK Commercial
UK All Companies
UK Equity Income
UK Smaller Companies
VCT AIM Quoted
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
Align Research
BNP Paribas Exane - Sponsored Research
BRR Media
Calvine Partners
Capital Access Group
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
goetzpartners securities Limited
Hardman & Co
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Radnor Capital Partners
Research Tree
SEAL Advisors Ltd
ShareSoc
Trinity Delta
Yellowstone Advisory
High Net Worth Offering
Fox-Davies Capital
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cenkos Securities
Couloir Capital
Dowgate Capital
finnCap
First Berlin
First Sentinel
Hannam & Partners
Hybridan
Liberum
Longspur Research
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
The Life Sciences Division
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane
BNP Paribas Exane - Sponsored Research
BRR Media
Bryan, Garnier & Co
Calderwood Capital
Calvine Partners
Canaccord Genuity
Capital Access Group
Cenkos Securities
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
finnCap
First Berlin
First Sentinel
Five Minute Pitch TV
goetzpartners securities Limited
Hannam & Partners
Hardman & Co
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Research
Magnitogorsk Iron and steel works
Mello Events
Northland Capital Partners
Numis
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Radnor Capital Partners
Research Tree
SEAL Advisors Ltd
Shard Capital
ShareSoc
Shore Capital
SI Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
The Life Sciences Division
Trinity Delta
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Video/Audio Interviews
BRR Media
Capital Access Group
Couloir Capital
Edison
Equity Development
Five Minute Pitch TV
piworld.co.uk
Proactive
QuotedData
RaaS - Research as a Service
Research Tree
Yellowstone Advisory
Event Providers
Capital Access Group
Cenkos Securities
Couloir Capital
Edison
Equity Development
Hardman & Co
InterAxS Global
Kepler | Trust Intelligence
London Stock Exchange
Mello Events
piworld.co.uk
QuotedData
Research Tree
ShareSoc
VSA Capital
Yellowstone Advisory
Contact
Sign Up
Sign In
Share: